Site Specific Conjugation of Hydrophobic Payloads Without Genetic Engineering
Site-specific conjugation leads to more homogeneous conjugates and allows control of the site of drug attachment. This approach frequently...
Understanding of the Underlying Mechanisms of Target-Independent Uptake and Toxicity
With 4 approved agents, antibody-drug conjugates or ADC have shown to be a very promising class of therapeutics. While the...
First-in-class Immunotherapeutic Approach Shows Efficacy in Neuroblastoma
Physician-scientists in the Cancer Center at Children's Hospital of Philadelphia (CHOP) have developed a preclinical, potent therapy attached to...
Novel Payloads for Antibody-drug Conjugates
The development of antibody-drug conjugates or ADCs, has resulted in the need of developing novel compounds that can be...
Experts Forecasts CMOs to Benefit from Double Digit Approvals of ADCs
The global ADC therapeutics market is expected to grow to US $ 4bn by 2023, with double digit approvals...
How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall?
In the aftermath of the fall of renowned breast cancer researcher Jose Baselga, MD, PhD, following revelations last month...
Benefitting from the Worldwide Supply Chain in the development of Antibody-drug Conjugates
Timing is everything. Just over a decade ago, the pharmaceutical industry and R&D in China was dominated by generics and...
Four Ways to Show Nonobviousness of ADC Inventions
As research continues to progress and the scientific community’s appreciation for the power of ADCs has grown, so have the numbers. FDA has now approved at least four ADCs, and hundreds more are in development. The number of patent applications has also grown, with the U.S. Patent and Trademark Office (USPTO) publishing over two hundred patent applications with claims to ADC inventions in the last two years alone.
Orphan Drug Designation for Alteogen’s Antibody-Drug Conjugate for the Treatment of Patients with Gastric...
Alteogen, a Korea-based biopharmaceutical company focusing on the development and commercialization of novel anticancer drugs such as antibody-drug conjugates,...
Study Evaluates Pyrrolobenzodiazepine (PBD)-dimers Containing Disulfide-based Prodrugs as Payloads for Antibody-Drug Conjugates
A number of cytotoxic pyrrolobenzodiazepine (PBD) monomers containing various disulfide-based prodrugs were evaluated for their ability to undergo activation...
